Somatic mosaic mutations in PPM1D and TP53 in the blood of women with ovarian carcinoma

JAMA Oncology

Volumn 2, Issue 3, 2016, Pages 370-372

  Swisher, Elizabeth M ^a   Harrell, Maria I ^a   Norquist, Barbara M ^a   Walsh, Tom ^b   Brady, Mark ^c   Lee, Ming ^b   Hershberg, Robert ^d   Kalli, Kimberly R ^e   Lankes, Heather ^c   Konnick, Eric Q ^b   Pritchard, Colin C ^b   Monk, Bradley J ^f   Chan, John K ^g   Burger, Robert ^h   Kaufmann, Scott H ^e   Birrer, Michael J ⁱ  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Statistical Office   (United States)

^d VentiRx Pharmaceuticals   (United States)

^e MAYO CLINIC   (United States)

^f ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^g CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHOPROTEIN PHOSPHATASE; PPM1D PROTEIN, HUMAN; PROTEIN P53; PROTEIN PHOSPHATASE 2C; TP53 PROTEIN, HUMAN;

AGE; AGED; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; MONONUCLEAR CELL; MOSAICISM; MUTATION; MUTATION RATE; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; MOSAICISM; MUTATION; MUTATION RATE; OVARIAN NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN PHOSPHATASE 2C; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85010637627     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.6053     Document Type: Article

References (7)

1. Ruark E, Snape K, Humburg P, et al; Breast and Ovarian Cancer Susceptibility Collaboration; Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013;493(7432):406-410.
2. AkbariMR, Lepage P, Rosen B, et al. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer. J Natl Cancer Inst. 2014;106 (1):djt323.
3. Zajkowicz A, Butkiewicz D, Drosik A, GiglokM, Suwiński R, RusinM. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. Br J Cancer. 2015;112(6):1114-1120.
4. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010;107(28): 12629-12633.
5. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108(44):18032-18037.
6. Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3): 764-775.
7. Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acutemyeloid leukaemia. Nature. 2015;518(7540):552-555.